Kalbitor (ecallantide)

ecallantide · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Kalbitor (ecallantide), covering 2011-01-17 to 2011-01-17. Get the full timeline:

Most recent: Clinical Trial Update: Outcomes and Safety Trial Investigating Ecallantide's Effect on Reducing Surgical Blood Loss Volume in Subjects at High Risk of Bleeding Exposed to Cardio-pulmonary Bypass During Cardiac Surgery [Phase 2]

See pricing